Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The methyl-CpG binding protein MBD1 is required for PML-RARalpha function.

Raffaella Villa1, Lluis Morey, Veronica A Raker

  • 1Centre de Regulacio Genomica, Universitat Pompeu Fabra, Passeig Maritim 37-49, 08003 Barcelona, Spain.

Proceedings of the National Academy of Sciences of the United States of America
|January 25, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adiponectin and phase angle in the assessment of sarcopenia in Crohn's disease: beyond muscle mass.

Frontiers in nutrition·2026
Same author

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

Journal for immunotherapy of cancer·2026
Same author

A framework for the exploration of subcellular compartmentalization of RNA-binding proteins.

Nature communications·2026
Same author

ASO Visual Abstract: A Prospective Randomized Trial Comparing Radioguided Occult Lesion Localization (ROLL) and Magnetic Seed Localization for the Localization of Nonpalpable Breast Lesions: Analysis of Surgical Outcomes, Patient's Perception, and Costs.

Annals of surgical oncology·2026
Same author

A Prospective Randomized Trial Comparing Radioguided Occult Lesion Localization (ROLL) and Magnetic Seed Localization for the Localization of Nonpalpable Breast Lesions: Analysis of Surgical Outcomes, Patient's Perception, and Costs.

Annals of surgical oncology·2026
Same author

Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status.

European journal of cancer (Oxford, England : 1990)·2026

PML-RARalpha causes acute promyelocytic leukemia by silencing genes. Researchers found that MBD1 and HDAC3 proteins cooperate with PML-RARalpha to maintain this gene silencing, blocking cell differentiation.

Area of Science:

  • Molecular Biology
  • Hematology
  • Epigenetics

Background:

  • PML-RARalpha fusion protein drives acute promyelocytic leukemia (APL).
  • Gene silencing via histone deacetylase (HDAC) and DNA methyltransferase recruitment underlies PML-RARalpha's function.
  • Understanding the molecular mechanisms of PML-RARalpha-mediated transcriptional repression is crucial for APL treatment.

Purpose of the Study:

  • To investigate the role of MBD1 (methyl-CpG binding domain protein 1) in PML-RARalpha-induced transcriptional repression and cellular transformation.
  • To elucidate the mechanism by which PML-RARalpha recruits MBD1 and its associated factors.

Main Methods:

  • RNA interference (RNAi) for HDAC3 knockdown in APL cells.
  • Retroviral expression of dominant-negative MBD1 mutants in hematopoietic precursors.

Related Experiment Videos

  • Chromatin immunoprecipitation (ChIP) to assess protein binding across gene loci.
  • Analysis of hematopoietic differentiation and gene expression.

    • Main Results:

    • MBD1 cooperates with PML-RARalpha in transcriptional repression and cellular transformation.
    • PML-RARalpha recruits MBD1 via an HDAC3-mediated mechanism to target gene promoters and loci.
    • HDAC3 knockdown alleviates PML-RARalpha-induced promoter silencing.
    • Expression of dominant-negative MBD1 mutants restores hematopoietic differentiation in the presence of PML-RARalpha.

    Conclusions:

    • PML-RARalpha functions by recruiting an HDAC3-MBD1 complex.
    • This complex establishes and maintains the silenced chromatin state essential for APL development.
    • Targeting the HDAC3-MBD1 complex may offer a therapeutic strategy for APL.